Stocks To Watch Today On June 1: IndiGo, Reliance, Glenmark Pharma, NMDC Among Key Shares In Focus Today
June 1 stock watch list highlights company-specific triggers. IndiGo reported a March-quarter net loss of Rs 2,536.3 crore vs profit Rs 3,067.5 crore; Glenmark Pharma net profit rose to Rs 301.4 crore. Lupin received USFDA approval for tablets; NMDC revenue +62% YoY and net profit +36%. Reliance rating upgraded by Moody’s; Suzlon plans to appeal a Rs 28.95 crore penalty.
New contract improves revenue visibility and can support order-book sentiment for near-term trading.
PNC Infratech won an EPC contract worth Rs 302.4 crore from the Airports Authority of India.
Mild upside bias; follow-through depends on whether the contract meaningfully expands order book.
Background
This is a multi-stock “stocks to watch” roundup for June 1, emphasizing earnings, regulatory approvals, contract wins, management changes, and credit-rating action.
Why it matters
Near-term trading is likely dominated by the specific catalysts: earnings prints (IndiGo, Glenmark, Inox Wind, Concord Biotech, NMDC), USFDA approval (Lupin), EPC contract (PNC Infratech), regulatory penalty/appeal (Suzlon), and Moody’s rating upgrade (Reliance).
Market relevance
Traders can use the listed catalysts to frame intraday positioning around earnings reaction, regulatory headlines, and credit/risk-premium signals.
Market effects
A mix of pharma regulatory approval (Lupin), pharma earnings strength (Glenmark), and industrial/credit-sensitive items (Inox Wind earnings weakness, Reliance credit upgrade) can shift sector sentiment intraday.
Primarily India-focused catalysts (Sensex/Nifty context, AAI contract, Indian lenders’ dividend), likely affecting local risk appetite and sector rotation.
Limited direct global linkage; Moody’s credit action on Reliance can modestly influence international credit/risk perceptions for Indian corporates.
Alternative perspectives
Some negative earnings headlines (IndiGo, Inox Wind) may already be partially priced; dividend/credit-upgrade items could be overreacted to without guidance changes.
The article lacks guidance, order-book size, and balance-sheet/capital ratio details—key for deciding whether these catalysts translate into sustained repricing.
Key entities
- companyInterGlobe Aviation (IndiGo)
Reported a large March-quarter net loss with profitability hit by weaker operating performance and exceptional items.
- companyGlenmark Pharma
Delivered a strong quarter with net profit jumping and margins improving materially.
- companyLupin
Received USFDA approval for specific tablets, adding to US pipeline.
- companyInox Wind
Reported sharply lower profit and weaker margins/revenue/EBITDA, driving share weakness.
- companyNMDC
Showed strong revenue and net profit growth despite margin pressure.
